Literature DB >> 17154493

4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species.

Vincenzo Summa1, Alessia Petrocchi, Victor G Matassa, Cristina Gardelli, Ester Muraglia, Michael Rowley, Odalys Gonzalez Paz, Ralph Laufer, Edith Monteagudo, Paola Pace.   

Abstract

The dihydroxypyrimidine carboxamide 4a was discovered as a potent and selective HIV integrase strand transfer inhibitor. The optimization of physicochemical properties, pharmacokinetic profiles, and potency led to the identification of 13 in the dihydroxypyrimidine series and 18 in the N-methylpyrimidinone series having low nanomolar activity in the cellular HIV spread assay in the presence of 50% normal human serum and very good pharmacokinetics in preclinical species.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17154493     DOI: 10.1021/jm060854f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

Review 2.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Arylation of Azaarylmethylamines with Aryl Chlorides and a NiBr2/NIXANTPHOS-based Catalyst.

Authors:  Gui Gao; Yue Fu; Minyan Li; Bo Wang; Bing Zheng; Shicong Hou; Patrick J Walsh
Journal:  Adv Synth Catal       Date:  2017-07-12       Impact factor: 5.837

5.  5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein.

Authors:  Savina Malancona; Mattia Mori; Paola Fezzardi; Marisabella Santoriello; Andreina Basta; Martina Nibbio; Lesia Kovalenko; Roberto Speziale; Maria Rosaria Battista; Antonella Cellucci; Nadia Gennari; Edith Monteagudo; Annalise Di Marco; Alessia Giannini; Rajhans Sharma; Manuel Pires; Eleonore Real; Maurizio Zazzi; Maria Chiara Dasso Lang; Davide De Forni; Francesco Saladini; Yves Mely; Vincenzo Summa; Steven Harper; Maurizio Botta
Journal:  ACS Med Chem Lett       Date:  2020-03-19       Impact factor: 4.345

6.  Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase.

Authors:  Karen A Kirby; Bruno Marchand; Yee Tsuey Ong; Tanyaradzwa P Ndongwe; Atsuko Hachiya; Eleftherios Michailidis; Maxwell D Leslie; Daniel V Sietsema; Tracy L Fetterly; Christopher A Dorst; Kamalendra Singh; Zhengqiang Wang; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Palladium-Catalyzed Benzylic C-H Arylation of Azaarylmethylamines.

Authors:  Byeong-Seon Kim; Jacqueline Jiménez; Feng Gao; Patrick J Walsh
Journal:  Org Lett       Date:  2015-11-17       Impact factor: 6.005

Review 8.  Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase.

Authors:  Angela Corona; Takashi Masaoka; Graziella Tocco; Enzo Tramontano; Stuart F J Le Grice
Journal:  Future Med Chem       Date:  2013-12       Impact factor: 3.808

9.  Antitubercular Triazines: Optimization and Intrabacterial Metabolism.

Authors:  Xin Wang; Daigo Inoyama; Riccardo Russo; Shao-Gang Li; Ravindra Jadhav; Thomas P Stratton; Nisha Mittal; Joseph A Bilotta; Eric Singleton; Thomas Kim; Steve D Paget; Richard S Pottorf; Yong-Mo Ahn; Alejandro Davila-Pagan; Srinivasan Kandasamy; Courtney Grady; Seema Hussain; Patricia Soteropoulos; Matthew D Zimmerman; Hsin Pin Ho; Steven Park; Véronique Dartois; Sean Ekins; Nancy Connell; Pradeep Kumar; Joel S Freundlich
Journal:  Cell Chem Biol       Date:  2019-11-08       Impact factor: 8.116

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.